Name: Dr. Oz: Fraud Findings Could Double Medicare Trust Fund Life
Uploaded: 2026-09-09T22:28:53+00:00
Duration: 513 s

Speakers

Mehmet Oz — Administrator for the Centers for Medicare and Medicaid Services

Kailey Leinz — Bloomberg Reporter

Summary

CMS Administrator Dr. Mehmet Oz discusses the administration's most favored nation drug pricing deals, Medicare GLP-1 coverage, fraud findings that could extend the Medicare trust fund, and health technology and price transparency efforts. He argues these policies lower drug costs and chronic disease spending. The conversation focuses on health policy and its implications for pharma, digital health, and government healthcare finances.

Dr. Oz touts the largest drop in consumer drug prices in 63 years from most favored nation pricing with top 26 branded pharma companies participating.
More drug pricing deals are in the works, and he wants Congress to codify the policy.
Medicare plans to cover GLP-1 obesity drugs at $50 per month versus $1,200, while Medicaid state uptake remains limited.
Treasury identified $20+ billion in suspected healthcare fraud and money laundering, which he says could double the Medicare trust fund life.
Access to medical records rose from 5% to 60%, supporting digital tools and technology to cut healthcare costs.
A coming CMS rule aims to make hospital prices more transparent.
Dr. Oz emphasizes prevention and obesity treatment to lower chronic disease spending.

Ideas

Mehmet Oz Administrator for the Centers for Medicare and Medicaid Services 0:15

US branded drug pricing faces structural pressure

Most favored nation drug pricing has already produced the largest drop in US consumer drug prices in 63 years; the top 26 branded pharmaceutical companies covering 90% of branded drugstore sales joined, with more pricing deals in the works and a push to codify the policy in Congress. This creates a structural pricing-pressure regime for US branded pharma.

Mehmet Oz Administrator for the Centers for Medicare and Medicaid Services 2:35

Medicare GLP-1 coverage expands; net impact unclear

Medicare is moving to cover GLP-1 obesity/weight-loss medications for eligible beneficiaries at $50 per month versus $1,200 previously, with the administrator arguing obesity treatment reduces chronic disease costs. This is a major utilization and policy development for weight-loss drugmakers, though the much lower administered price makes the net industry impact uncertain.

Mehmet Oz Administrator for the Centers for Medicare and Medicaid Services 5:51

Policy tailwind for healthcare technology adoption

CMS increased the share of Americans with easy access to their medical records from 5% to 60%, and Dr. Oz argues opening those data pipelines will allow technology and digital tools to give patients better guidance and reduce health costs. That is a policy tailwind for healthcare technology and digital health adoption.

This Bloomberg Markets video, published September 09, 2026, features Mehmet Oz discussing US branded pharmaceutical companies, GLP-1 weight-loss drugmakers, XLV. 3 trade ideas extracted by AI with direction and confidence scoring.

Speakers: Mehmet Oz · Tickers: US branded pharmaceutical companies, GLP-1 weight-loss drugmakers, XLV

Dr. Oz: Fraud Findings Could Double Medicare Trust Fund Life

Summary

Ideas

Up Next